Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, is pleased to announce that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, according to a preliminary list of additions posted June 4.

Hepion Pharmaceuticals to be Added to the Russell Microcap® Index

EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it has completed recruitment for its Phase 2a ‘AMBITION' clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled.

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

EDISON, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, announced that its Senior Vice-President, Clinical Pharmacology and Analytics, Dr. Patrick Mayo, gave a virtual presentation entitled “CRV431 – From Benchtop to Bedside Clinical Development” today at the 4th Global NASH Congress.

Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress

Agile Therapeutics

Aqua Metals

Catabasis Pharmaceuticals

Checkpoint Therapeutics

InflaRx

Limelight Networks

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

7 Penny Stocks That May Have Room to Run Higher

The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased by over 5% pre-market. This is why it happened.

HEPA Stock Price Increases Over 5% Pre-Market: Why It Happened

EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).1

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431

ENDRA Life Sciences

Hepion to include ENDRA's TAEUS Ⓡ technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic drug development for the treatment of NASH and liver disease, announced today the signing of a collaboration agreement to incorporate TAEUS as an add-on technology to support Hepion's patient screening and biomarker measurement during the upcoming Phase 2b study of CRV431. "We are thrilled to partner with Hepion Pharmaceuticals in the further clinical development of CRV431," said ENDRA's Chairman and Chief Executive Officer Francois Michelon.

ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials

EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that it will present at the NASH-TAG 2021 Conference, being held virtually on March 11-13. The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $88.4 million before deducting underwriting discounts, commissions and other offering expenses. All of the shares of common stock are being offered by the Company.

Hepion Pharmaceuticals Announces Pricing of Public Offering

Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated.

Attractive Risk-Reward Profile For Hepion Pharmaceuticals

EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, announced today that management will participate in two virtual investor conferences in January. H.C. Wainwright BioConnect 2021 Conference (January 11-14, 2021): Hepion's pre-recorded presentation will be available for approximately 90 days on its website at www.hepionpharma.com under "Events" in the Investors section, beginning on Monday, January 11, 2021.

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences

CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / ACCESSWIRE / December 29 , 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be Completed in Early 2021 - EDISON, NJ / ACCESSWIRE /  December 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, "Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that an independent Data Safety Monitoring Board ("DSMB") has approved the continuation of the Company's Phase 2a 'AMBITION' clinical trial. Two interim analyses were performed by a DSMB to evaluate the safety and tolerability of the 75 mg CRV431 dose cohort in NASH patients.

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID-19 Drug Development - EDISON, NJ / ACCESSWIRE / December 22, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its investigational new drug ("IND") application for CRV431, a novel cyclophilin inhibitor for the treatment of COVID-19. On July 7, 2020, Hepion announced a potential two-pronged strategy to treat COVID-19.

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Hepion Pharmaceuticals (HEPA) Jumps: Stock Rises 9%

Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock?

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading higher after the company reported its CRV431 demonstrated efficacy in Kidney Fibrosis.

Why Hepion Pharmaceuticals Is Trading Higher Today

Allied Healthcare Products

Gilead Sciences

GenMark Diagnostics

Novartis

Regeneron Pharmaceuticals

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Coronavirus Pandemic Requires Patient Investing And A Focused Portfolio

Heidrick & Struggles International

JBG SMITH Properties

Northwest Bancshares

Hanover Insurance Group

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

'5 Stocks' in Focus as Analysts Initiate Coverage

Coca-Cola Femsa SAB de CV

Buy These 5 Stocks as New Analysts Initiate Coverage

Hepion Pharmaceuticals And Neoleukin Therapeutics: Two Micro Cap Pharmaceutical Stocks Priced For "Non Success" With Promising Drugs

Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs

Shares of Hepion Pharmaceuticals Inc (NASDAQ: HEPA), formerly ContraVir Pharma, are ripping higher after the thinly-traded, nano-cap biotech announced results from an animal study of its lead product candidate CRV431.

Hepion Rips Higher After NASH Drug Confirms Antifibrotic Activity In Animal Study

Shares of Hepion Pharmaceuticals Inc. rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 liver cirrhosis treatment.

News for Hepion Pharmaceuticals Inc Stock (HEPA)